Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Curie-Cancer Trebles Early Phase Clinical Research Studies with Industry Partners

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Ten early stage clinical studies (phase I) were conducted in 2012, trebling since 2010 and continuing to grow in 2013.

Curie-Cancer has announced a strong increase in the number of early stage clinical trials (phase I) from three in 2010 to ten in 2012. The studies are being conducted with industry partners.

The rise in the number of studies is a direct result of the changes in strategic direction put in place by professor Pierre Teillac, director of the Institut Curie Hospital Group and the recent launch of the Clinical Research Department, headed by Veronique Dieras, in response to the needs of industry partners.

These studies aim to evaluate a compound’s safety and pharmacokinetics (absorption rate, elimination rate, maximum blood concentration, etc.) in patients to establish the subsequent dosage of the drug.

The studies also research the first signs of efficacy. These studies are becoming increasingly crucial to the pharmaceutical companies, who seek experienced investigation that is reliable, efficient and reduces turnaround.

“The 2012 increase in early stage clinical trials for Curie-Cancer is rather remarkable. Due to contracts signed at the start of 2013, we expect the number to continue to climb significantly,” said Christophe Le Tourneau, the oncologist responsible for the Institut Curie’s early stage clinical studies.

Tourneau continued, “We have many diverse industry partners working on studies of different types of cancer. They range from French SMEs to international groups.”

Dr Patricia Tresca, who has extensive experience within the pharmaceutical industry, now leads the body in charge of managing clinical trials for Curie-Cancer.

She was recruited for her working knowledge of the industry partner types Curie-Cancer targets. Curie-cancer has been tasked with improving responsiveness and inclusion rates in patients.

It will help industry partners to obtain the reports they need in time to make their decisions faster. Industry partners will also be able to request the necessary authorizations from the monitoring authorities in order to proceed to the next development stages.

Curie-Cancer’s main advantage is achieving the close collaboration between research doctors, who are conducting the trials and the researchers in charge of translational and/or fundamental research.

In the age of genomics and proteomics, preliminary studies are often best conducted at the cutting edge of academic research. As researchers are involved in conducting the preclinical studies, they are in a position to best interpret the results.

They can therefore make the right decisions quickly. An increasing number of the products studied in “first in man“ trials at the Institut Curie have also been studied previously in preclinical studies commissioned by industry partners with different research laboratories on campus.

Another advantage is Curie-Cancer’s ability to conduct early stage clinical studies for industry partners accustomed to commissioning preclinical studies with them.

They know that the partnership will bring benefits from conducting further clinical studies of their products in development.

The opportunity for researchers to participate in these early stage studies, upon which the future of many products is decided, is very interesting. It allows them to link concepts derived in a laboratory, through in vitro or animal test results, to the first observations in patients.

“Clinical research has meaning only if it makes innovative products available to patients. Allowing early stage access to these products in development within pharmaceutical laboratories is an additional opportunity for those whose commercially available products are not efficient enough,” said Damien Salauze, director of Curie-Cancer.

Salauze continued, “We are pleased that the expertise and knowledge that Curie-Cancer brings to our industry partners can be combined with added hope for patients.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curie-Cancer and Strand Launch Curie Image Database
A breakthrough image management platform for scientists.
Wednesday, December 18, 2013
Curie-Cancer and Meiogenix Sign Two Partnership Agreements
Curie-Cancer and Meiogenix will develop the SpiX technology in yeast and in mice to unlock unexplored genetic diversity.
Tuesday, November 19, 2013
Curie-Cancer and Harmonic Pharma Sign a Partnership Agreement
Under this multi-year research collaboration, Curie-Cancer will give Harmonic Pharma access to its extensive collection of patient-derived xenografts representative of human tumors.
Tuesday, November 06, 2012
Scientific News
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Biologists Find Unexpected Role for Amyloid-Forming Protein
Yeast protein could offer clues to how Alzheimer’s plaques form in the brain.
Revolutionary Gene-editing Technique to Stop AIDS Virus in Its Tracks
UNLV personalized medicine researchers seeking patent on potential HIV cure. Their technique uses a plant protein widely used in agriculture industry.
Viruses Join Fight Against Harmful Bacteria
Engineered viruses could combat human disease and improve food safety.
Tracking Changes in DNA Methylation In Real Time At Single-Cell Resolution
Whitehead Institute researchers have developed a methodology to monitor changes in DNA methylation over time in individual cells.
Virus Re-Engineered to Deliver Targeted Therapies
Researchers stripped a virus of its infectious machinery and turned its benign core into a delivery vehicle that can target sick cells while leaving healthy tissue alone.
Exposure to Pesticides In Childhood Linked to Cancer
Young children who are exposed to insecticides inside their homes may be slightly more at risk for developing leukemia or lymphoma during childhood, according to a meta-analysis by Harvard T.H. Chan School of Public Health researchers.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos